Pacira BioSciences has announced FDA clearance for its Iovera system, enhanced with a longer-needle Smart Tip, for the treatment of chronic low back pain. This new application of the cryoneurolysis technology offers a non-opioid option for patients suffering from persistent back pain.
The Iovera system functions by applying targeted cold therapy to peripheral nerves, a process known as cryoneurolysis. This temporarily interrupts the nerve's ability to transmit pain signals, providing relief that can last for several months. The longer-needle Smart Tip is designed for use through a cannula or introducer, enabling ice ball formation at deeper peripheral nerves.
Clinical Evidence and Benefits
A pilot study comparing Iovera cryoneurolysis to radiofrequency ablation (RFA) for chronic back pain demonstrated the potential advantages of the Iovera system. Patients treated with Iovera reported lower pain scores and improved functional outcomes over a one-year period, with no serious adverse events observed.
Dr. Jonathan Slonin, Chief Medical Officer of Pacira, emphasized the significance of this FDA clearance, stating it represents "a crucial advancement in providing a drug-free solution for long-lasting pain relief." He further noted the company's dedication to enhancing the lives of individuals affected by chronic back pain.
Addressing Chronic Low Back Pain
Chronic low back pain is a widespread and debilitating condition in the United States, often leading to disability, missed workdays, and potential opioid dependency. The Iovera system offers a promising alternative by directly targeting the nerves responsible for transmitting pain signals without the use of pharmaceuticals.
Pacira's Broader Pain Management Portfolio
Pacira BioSciences is known for its commitment to non-opioid pain management solutions. Their portfolio includes EXPAREL for postsurgical pain and ZILRETTA for osteoarthritis knee pain. The Iovera system complements these offerings by providing a drug-free approach to pain control through targeted cold temperature application.
Financial Health and Future Outlook
Pacira's recent financial performance indicates a solid foundation for continued innovation and growth. The company reported revenue growth of 4.4% in the last twelve months and maintains a strong current ratio of 2.25. With ongoing advancements in their non-opioid pain therapies, including the planned Phase 2 study for PCRX-201 in 2025, Pacira is poised to further impact the pain management landscape.
